Compared to existing molecular tools for colorectal cancer staging—such as APC, KRAS, BRAF, NRAS and PIK3CA mutations—our study offers a novel transcriptomic perspective by identifying stage-specific gene expression signatures that distinguish adenoma, CIS and adenocarcinoma. Here, KRAS is linked to in situ carcinoma.